An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
NCT01975636
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
113
Enrollment
INDUSTRY
Sponsor class
Conditions
Metabolism and Elimination
Interventions
DRUG:
E2609
Sponsor
Eisai Inc.